Chris Ryan

Chris Ryan joined OncLive in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Articles

Hematology Experts Outline the Top Abstracts to Watch at the 2025 ASCO Annual Meeting

May 19th 2025

Oncology experts detail their most highly-anticipated hematology abstracts and data to watch at the upcoming 2025 ASCO Annual Meeting.

Dr Tarantino on the Potential Relevance of the DESTINY-Breast09 Trial in HER2+ Breast Cancer

May 16th 2025

Paolo Tarantino, MD, PhD, discusses potentially practice-changing breast cancer research that will be presented at the 2025 ASCO Annual Meeting.

Dr Maroto-Martin on the Development of MZB1 TCR-Like CAR T-Cell Therapy in Myeloma

May 16th 2025

Elena Maroto-Martin, PhD, discusses the rationale for developing TCR-like CAR T-cell therapy in multiple myeloma and other hematologic malignancies.

Dr Garcia on the Safety of Earlier Use of Lu 177 Vipivotide Tetraxetan PSMA+ mCRPC

May 16th 2025

Jorge A. Garcia, MD, discusses the safety of Lu 177 vipivotide tetraxetan earlier in the treatment course for PSMA–positive mCRPC.

Dr Pimenta on Ongoing Therapeutic Challenges in Soft Tissue Sarcomas

May 16th 2025

Erica Maria Pimenta, MD, discusses ongoing therapeutic and translational challenges in the treatment of soft tissue sarcomas.

Durvalumab Plus Tremelimumab and Trastuzumab Yields Clinical Activity in Trastuzumab-Resistant HER2+ Breast Cancer

May 16th 2025

Durvalumab plus tremelimumab and trastuzumab produced responses in trastuzumab-resistant, HER2-positive advanced breast cancer.

Analysis of PADA-1 Trial Highlights Kinetics and Determinants of ESR1 Mutations in HR+/HER2– Metastatic Breast Cancer

May 16th 2025

An analysis from PADA-1 showed the emergence of ESR1 mutations was uneven over time in hormone receptor–positive, HER2-negative metastatic breast cancer.

Dr Sabari on the Activity of Zongertinib in Pretreated, Advanced, HER2-Mutated NSCLC

May 15th 2025

Joshua K. Sabari, MD, discusses how phase 1 efficacy data with zongertinib in HER2-mutant NSCLC lay the foundation for future research with the agent.

Puxitatug Samrotecan Yields Responses With Manageable Safety in Pretreated HR+/HER2– Advanced Breast Cancer

May 15th 2025

Puxitatug samrotecan demonstrated manageable safety and early efficacy in HR-positive/HER2-negative advanced breast cancer.

First-Line Eftilagimod Alpha Plus Pembrolizumab/Chemo Yields Responses in Advanced Nonsquamous NSCLC

May 15th 2025

First-line eftilagimod alpha plus pembrolizumab and chemotherapy produced responses in advanced nonsquamous non–small cell lung cancer.

FDA Green Lights Companion Diagnostic for Telisotuzumab Vedotin in NSCLC

May 15th 2025

The FDA has approved the VENTANA MET (SP44) RxDx Assay as a companion diagnostic for telisotuzumab vedotin in non–small cell lung cancer.

Pembrolizumab-Based Regimen Yields PFS Benefit in Platinum-Resistant Ovarian Cancer

May 15th 2025

Pembrolizumab/paclitaxel with or without bevacizumab improved PFS vs placebo/chemotherapy with or without bevacizumab in platinum-resistant ovarian cancer.

FDA Approval of Penpulimab Expands Treatment Options in Recurrent/Metastatic Non-Keratinizing NPC

May 15th 2025

Aditya Shreenivas, MD, MS, discusses the FDA approval of penpulimab for recurrent/metastatic non-keratinizing NPC.

Dr Grisham on the FDA Approval of Avutometinib/Defactinib for KRAS+ Recurrent Low-Grade Serous Ovarian Cancer

May 14th 2025

Rachel Grisham, MD, discusses the FDA approval of avutometinib plus defactinib for KRAS-mutated, recurrent low-grade serous ovarian cancer.

Dr Falchi on the Efficacy of Fixed-Duration Epcoritamab Plus Lenalidomide and Rituximab in R/R Follicular Lymphoma

May 14th 2025

Lorenzo Falchi, MD, discusses the safety and efficacy of fixed-duration epcoritamab plus lenalidomide and rituximab in relapsed/refractory follicular lymphoma.

FDA Grants Accelerated Approval to Telisotuzumab Vedotin In Pretreated Advanced NSCLC With c-MET Overexpression

May 14th 2025

The FDA approved telisotuzumab vedotin for pretreated advanced NSCLC harboring high c-MET protein overexpression.

FDA Approves Belzutifan for Advanced Pheochromocytoma and Paraganglioma

May 14th 2025

The FDA has approved belzutifan for advanced, unresectable, or metastatic pheochromocytoma and paraganglioma.

Generic Eltrombopag Is Now Available for Severe Aplastic Anemia and Immune Thrombocytopenia

May 14th 2025

Generic formulations of eltrombopag are now available for severe aplastic anemia and immune thrombocytopenia.

Breast Cancer Experts Bookmark Top Abstracts to Watch at the 2025 ASCO Annual Meeting

May 14th 2025

To prepare for the 2025 ASCO Annual Meeting, breast cancer experts share the abstracts and discussions they’re most excited to see at the meeting.

Dr Dorff on a Real-World Study of Relugolix in Advanced Prostate Cancer

May 13th 2025

Tanya B. Dorff, MD, discusses the clinical characteristics and treatment preferences for initiating relugolix during prostate cancer treatment

x